Article
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
British journal of haematology - 1 Aug 2020
Farah Nadine, Burt Richard, Ibrahim Amr R, Baker Robert, Kottaridis Panagiotis D
Abstract excerpt
No abstract is available from the source.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.